Astra Expects U.S. Trial Update Within Two Weeks, Analyst Says

AstraZeneca Plc told analysts it expects an update in the next one to two weeks on its halted U.S. trial evaluating the coronavirus vaccine under development with the University of Oxford and believes the study could resume this year, according to a note from Guggenheim Securities.

The drugmaker expects global approval will be determined by results in tests outside the U.S., Guggenheim analysts wrote, citing comments from Mene Pangalos, the head of biopharma research. The British company sees the U.S. trial as “more of a confirmatory” study, according to the report.